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Abstract 37	  
 38	  
Between 5-70% of genetic disease is caused by in-frame nonsense mutations, which 39	  
introduce a premature termination codon (PTC) within the disease-causing gene. 40	  
Consequently, during translation, non-functional or gain-of-function truncated 41	  
proteins of pathological significance, are formed. Approximately 50% of all inherited 42	  
retinal disorders have been associated with PTCs, highlighting the importance of 43	  
novel pharmacological or gene correction therapies in ocular disease. 44	  
Pharmacological nonsense suppression of PTCs could delineate a therapeutic 45	  
strategy that treats the mutation in a gene- and disease-independent manner. This 46	  
approach aims to suppress the fidelity of the ribosome during protein synthesis so 47	  
that a near-cognate aminoacyl-tRNAs, which shares two of the three nucleotides of 48	  
the PTC, can be inserted into the peptide chain, allowing translation to continue, and 49	  
a full-length functional protein to be produced. Here we discuss the mechanisms and 50	  
evidence of nonsense suppression agents, including the small molecule drug 51	  
ataluren (or PTC124) and next generation ‘designer’ aminoglycosides, for the 52	  
treatment of genetic eye disease.  53	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1. Introduction 75	  
 76	  
An estimated 11.2% of human genetic disease is caused by in-frame, nonsense 77	  
mutations,1 resulting in the premature introduction of a termination codon, (UAA, 78	  
UAG or UGA), in the mRNA transcript. When translated, this generates a truncated, 79	  
often dysfunctional polypeptide through premature ribosome dissociation. The 80	  
resulting abrogated protein can exert a knock-out, dominant-negative or gain-of-81	  
function effect on gene function, dependent on the gene affected.2 With this in mind, 82	  
the efficiency of translation termination has been described as a therapeutic target 83	  
for human pathologies resulting from premature termination codons (PTCs). 84	  
  85	  
The classical approach involves gene replacement therapy to restore protein 86	  
production by the introduction of gene cassettes. For example, adeno-associated 87	  
viral (AAV) vectors allow localised and systemic delivery of the desired gene carrying 88	  
the correct sequence to the target tissue. Although several clinical trials have 89	  
demonstrated encouraging results, a number of issues surround the efficacy of such 90	  
treatments,3 for example, the possibility of donor DNA integration into unwanted sites 91	  
in a patient's genome which could cause harmful off-target effects.4, 5 Additionally, 92	  
many large genes exceed the current packaging limits of viral vectors, for example, 93	  
USH2A, responsible for Usher syndrome type II (see section 6.4), encodes two 94	  
mRNA transcripts, the largest of which is 18 Kb.6 Furthermore, difficulties may arise 95	  
in accurately engineering the expression of tightly regulated disease-causing genes, 96	  
for example transcription factors, where different transcript levels can encourage 97	  
target tissue-specific phenotype variability.  98	  
 99	  
A novel approach known as nonsense suppression therapy or translational bypass 100	  
readthrough is under investigation to treat PTC-derived diseases, based on the 101	  
discovery that certain compounds, namely aminoglycosides, can promote a low level 102	  
of eukaryotic ribosomal readthrough of PTCs.7-9 For many recessive, loss of function 103	  
disorders, especially metabolic disease, only small amounts of functional protein can 104	  
be therapeutically relevant in improving function and halting disease progression.10  105	  
 106	  
Nonsense suppression therapy allows the affected gene to remain under the control 107	  
of natural regulatory mechanisms and there is also no gene size limitation. To date, 108	  
most notably, nonsense suppression has been employed in the treatment of cystic 109	  
fibrosis (CF) and Duchenne muscular dystrophy (DMD), for which effective curative 110	  
therapies are currently lacking.7, 11-13 In ophthalmology, the first phase II clinical trial 111	  
for aniridia using Translarna™ (also known as ataluren or PTC124) has commenced 112	  
(NCT02647359). In-frame PTCs contribute to approximately 30% of genetic eye 113	  
disorders and recent preclinical research indicates that topical and systemic 114	  
administration of readthrough compounds can ameliorate nonsense-mediated ocular 115	  
disease phenotypes. In this review we discuss the mechanisms governing nonsense 116	  
suppression and their relevance to ocular genetic disorders, providing evidence for 117	  
the application of nonsense suppression therapy as a viable therapeutic option for 118	  
untreatable genetic eye diseases and multi-system disorders with ocular 119	  
involvement. 120	  
 121	  
2. Mechanism of nonsense suppression therapy 122	  
 123	  
During normal translation, free tRNAs are sampled at the aminoacyl (A)-site of the 124	  
eukaryotic ribosome. Both cognate aminoacyl-tRNAs (perfectly matched base pairs) 125	  
and near-cognate aminoacyl-tRNAs (containing two of the three base pairs) can 126	  
interact with the A-site. Once a cognate aminoacyl-tRNA is detected and 127	  
accommodated to the empty A-site, enzymatic attachment of the amino acid to the 128	  
polypeptide chain can occur.14 This results in translocation of the tRNA-polypeptide 129	  
complex into the P-site, hence vacating the A-site and allowing the next codon in the 130	  
mRNA sequence to be sampled and translated (Figure 1). When a ribosome 131	  
encounters a stop codon in the mRNA sequence, there is no cognate aminoacyl-132	  
tRNA that can bind to the sequence. Instead, interplay between eukaryotic release 133	  
factors (eRFs), eRF1 and eRF3 facilitates peptidyl-tRNA hydrolysis and release of 134	  
the newly formed polypeptide by forming a ‘termination complex.’ eRF1 recognizes 135	  
and binds the stop codon at the A-site instead of a cognate aminoacyl tRNA, thereby 136	  
altering the activity of the ribosomal peptidyl transferase. The GTPase eRF3, 137	  
stimulates peptide release by eRF1 in a GTP-dependent manner.15-17  138	  
 139	  
Near-cognate aminoacyl-tRNAs are able to compete with eRFs for binding of the 140	  
stop codon in the A-site.18 This leads to the incorporation of the corresponding amino 141	  
acid into the growing polypeptide chain and translocation of this tRNA-peptide 142	  
complex into the P-site, effectively allowing ‘readthrough’ of the stop codon (Figure 143	  
1C). Each stop codon can be translated through nonsense suppression using a 144	  
specific group of near-cognate amino acids (Table 1). In humans, under normal 145	  
conditions, readthrough of PTCs occurs in <1% of translation events and 146	  
suppression of natural termination codons occurs at a frequency of <0.1%.19 Basal 147	  
levels of readthrough of nonsense mutations are too low to retrieve functionality, 148	  
however, further increases in functional protein may rescue disease pathology.10 149	  
Several compounds that increase the readthrough of PTCs have demonstrated 150	  
potential in the treatment of genetic disorders caused by nonsense mutations, where 151	  
the recovery of small amounts of functionally active protein can be therapeutic 152	  
particularly in loss-of-function recessive disorders.20  153	  
 154	  
3. Nonsense suppression compounds 155	  
 156	  
3.1 Aminoglycosides 157	  
 158	  
Aminoglycosides are bactericidal antibiotics composed of small, di-/tri- saccharide 159	  
units joined by glycosidic linkages (Figure 2). They bind to the adenosine nucleotide 160	  
in the rRNA sequence at position 1408 in the prokaryotic A-site, resulting in 161	  
ribosomal infidelity, poor codon recognition and the production of jumbled, non-162	  
functional proteins leading to bacterial cell death. Eukaryotic ribosomes contain a 163	  
guanosine nucleotide in this position, which can confer resistance to certain 164	  
aminoglycosides as proper Hydrogen bonding between amino and hydroxyl 165	  
functional groups of aminoglycosides and RNA bases in the A-site are not formed. 166	  
For example, 6’-NH2 containing aminoglycosides, such as kanamycin A demonstrate 167	  
lower affinity for the eukaryotic rRNA sequence than the prokaryotic equivalent.18, 21-23  168	  
 169	  
The relationship between readthrough efficacy and the induction of A-site structural 170	  
changes during aminoglycoside-mediated nonsense suppression is not well 171	  
understood.21, 24, 25 It has been hypothesized that the decoding mechanism by which 172	  
the ribosomal machinery deciphers the mRNA code in the A-site is conserved 173	  
between pro- and eukaryotes, but the mechanism of drug action appears to differ.21 174	  
A number of aminoglycosides have demonstrated nonsense suppression activity 175	  
including: gentamicin, paromomycin, geneticin (G418), streptomycin, lividomycin, 176	  
and tobramycin, in multiple tissues and disease models, in vivo and in vitro, 177	  
highlighting a promising clinical application to alleviate the consequences of a 178	  
multitude of hereditary disorders.7-9, 26 Of the aminoglycosides described, G418, 179	  
gentamicin and paromomycin are capable of the broadest and most efficacious PTC 180	  
readthrough activity.21, 27-29 Readthrough efficacy not only varies between genes, but 181	  
is also dependent on the type and location of the termination codon in the gene of 182	  
interest and on the surrounding mRNA sequence context. Some stop codons are 183	  
more susceptible to readthrough than others; a predilection for UGA>UAG>UAA, has 184	  
been described,18 although one study described no correlation between stop codon 185	  
identity and response to gentamicin-treatment.30  186	  
 187	  
The efficiency of translational readthrough of PTCs can vary as a consequence of 188	  
mRNA secondary structures, for example downstream stem-loop structures can 189	  
induce ribosomal pausing. Additionally, nucleotide context of the PTC seems 190	  
important in determining readthrough efficiency.30 Cytosine residues at position +4 191	  
(immediately downstream from the stop codon), facilitated a higher level of 192	  
readthrough than uracil, guanine or adenine (C>U>G≥A) either in the presence or 193	  
absence of aminoglycosides.18, 30 The presence of a uracil residue in the -1 position, 194	  
was associated with higher levels of gentamicin-induced readthrough than any other 195	  
nucleotide. Although the chemical properties of the nascent polypeptide chain have 196	  
been reported to modulate translational readthrough in these investigations, these 197	  
rules are not definitive in predicting readthrough efficacy, for example, the order of 198	  
hierarchy of the +4 residue may rotate depending on which stop codon is employed18 199	  
and combined effects between specific residues in different positions have been 200	  
noted for induced-readthrough.30 201	  
 202	  
3.1.1 Aminoglycosides – Clinical delivery 203	  
 204	  
Although aminoglycosides have demonstrated considerable potential for therapeutic 205	  
application of the readthrough mechanism, problems persist. Aminoglycosides such 206	  
as gentamicin are not lipid soluble and have difficulty penetrating cells when 207	  
administered systemically.31 Most notably, challenges of effective systemic delivery 208	  
to the retina or cerebrospinal fluid, where limited penetration across the blood-retinal 209	  
or blood-brain barrier remain. Liposome-encapsulation of aminoglycosides has been 210	  
attempted to achieve intracellular delivery therefore optimizing therapeutic efficacy by 211	  
increasing delivery of the drug to the cytoplasm of the cell.32 Amikacin accumulated 212	  
at higher concentrations and persisted longer in tissues of mice treated with 213	  
liposome-encapsulated drug when compared to administration of the free compound 214	  
at an equivalent dose, hence prolonging exposure to the pharmacological effects of 215	  
the drug.33 Importantly, mice that received a dose of free amikacin excreted most of 216	  
the administered dose in the urine within the first day of treatment.  217	  
 218	  
3.1.2 Aminoglycosides – Toxicity 219	  
 220	  
Severe drug toxicity at therapeutically relevant levels limits the clinical utility of long-221	  
term aminoglycoside treatment.18, 34, 35 Aminoglycosides are nephrotoxic and ototoxic 222	  
due to the enriched presence of endocytic megalin receptors, the primary mediator of 223	  
aminoglycosidic uptake, on the surface of epithelial cells of the renal proximal tubules 224	  
and hair cells of the inner ear.36 Additionally, aminoglycosides possess 225	  
neuromuscular blocking activity.27  226	  
 227	  
The gentamicin complex is naturally produced by the bacterium Micromonospora, as 228	  
a mixture of five structurally related active compounds or congeners (C1, C1a, C2, 229	  
C2a and C2b). Each congener exhibits different readthrough efficacy and toxicity. 230	  
Initial studies suggested that gentamicin nephrotoxicity was largely attributable to the 231	  
C2 congener. Conversely, more recently the isolated C2 congener exhibited low 232	  
cellular toxicity in in vitro mouse cytotoxicity assays and showed reduced 233	  
nephrotoxicity in rats in vivo, when compared to treatment with the native gentamicin 234	  
compound.37 A further study suggested the C2 congener induced the strongest 235	  
ototoxic effects, whilst C1 and C1a were the least severe in rats treated 236	  
intratympanically with the isolated congeners.38 Understanding the relative toxicity of 237	  
the individual congeners would facilitate development of custom-made 238	  
aminoglycosidic therapies without sacrificing nonsense suppression capacity.  239	  
 240	  
Ototoxic mechanisms of aminoglycosides may also be due to the inhibition of 241	  
mitochondrial protein synthesis. Mitochondria share evolutionary lineage with 242	  
prokaryotic cells and aminoglycosides preferentially bind to the prokaryotic, rather 243	  
than the eukaryotic, ribosomal A-site.39 Inhibition of mitochondrial protein synthesis 244	  
leads to the oxidative inactivation of mitochondrial aconitase, as a result of 245	  
superoxide production and the dose- and time-dependent mobilization of free ferrous 246	  
iron. Cells ultimately undergo apoptosis via the Fenton reaction, as demonstrated by 247	  
the auditory sensory cell damage in aminoglycoside-treated cochlear explants and in 248	  
guinea-pigs in vivo.39, 40  249	  
 250	  
The co-administration of aminoglycosides with antioxidants significantly reduced 251	  
oxidative damage, therefore potentiating some level of hair cell protection.41 The 252	  
mechanism of reactive oxygen species (ROS)-mediated damage to mitochondrial 253	  
aconitase remains unclear, however, aminoglycosides modified to exhibit greater 254	  
specificity for cytoplasmic rRNA rather than mitochondrial rRNA, have reduced 255	  
ototoxic potential. For example, the aminoglycoside G418 and designer 256	  
aminoglycoside NB84 exhibit similar efficacy of inhibition of cytoplasmic protein 257	  
synthesis, but G418 has a 30-fold higher propensity to inhibit mitochondrial protein 258	  
synthesis. NB84 exhibits reduced ototoxic potential as a result of decreased affinity 259	  
for mitochondrial rRNA.39, 40 All studies investigating the efficacy of liposome-260	  
encapsulated aminoglycosides in animals reported a reduction in acute toxicity when 261	  
compared to administration of the free drug.33 Additionally, co-administration of 262	  
calcium cation can antagonize the acute toxicity and neuromuscular blocking effects 263	  
of aminoglycoside treatment, and co-administration of poly-L-aspartate or 264	  
daptomycin to concentrate aminoglycosides in the cytoplasm, confers a level of renal 265	  
protection, and enhances nonsense suppression.42, 43 266	  
 267	  
Intraocular administration of aminoglycosides has been associated with retinal 268	  
toxicity for the treatment of endophthalmitis, leading ophthalmologists to search for 269	  
other Gram-negative targeting antibiotics for routine intravitreal injections.44 Initial 270	  
case reports demonstrated that administration of gentamicin, amikacin or tobramycin 271	  
caused vision loss with a pale fundus, intraretinal hemorrhages, arteriolar narrowing 272	  
and venous beading.45 More chronic findings included neovascular glaucoma, 273	  
pigmentary degeneration, optic atrophy and severe visual loss.46 Lavage of the 274	  
anterior chamber and early vitrectomy, in some cases, prevented such vision loss.47 275	  
More recent in vitro and in vivo ERG studies in rabbits and rats showed that the b-276	  
wave in electroretinography was completely eliminated by high-dose gentamicin 277	  
treatment, with diffuse disruption of the nerve fiber layer and inner plexiform layers of 278	  
the eye.48 These effects were reversible with short-term exposure to gentamicin. 279	  
Despite multiple case reports of macular infarction after intravitreal injection of 280	  
aminoglycosides, amikacin is still administered intravitreally with vancomycin in 281	  
cases of endophthalmitis.  282	  
 283	  
3.2. Designer aminoglycosides 284	  
 285	  
Discovery efforts to produce new readthrough compounds with lesser toxicity than 286	  
aminoglycosides have been driven by rational synthesis, focusing on the 287	  
manufacture of designer derivatives of existing drugs.28 ‘Designer aminoglycosides’ 288	  
maintain the natural aminoglycoside backbone, but the attachment of various 289	  
structural appendages allows for the selection of favourable bioactivity and toxicity 290	  
properties (Figure 2). The nomenclature for designer aminoglycosides is as follows: 291	  
neomycin derivatives have the prefix TC-, paromomycin derivatives the prefix NB-, 292	  
and kanamycin derivatives the prefix JC-.1  293	  
 294	  
In the case of the NB-compounds, it was suggested that a C6’-hydroxyl group was 295	  
important for readthrough efficacy, given that this was conserved in both 296	  
paromomycin and G418, two of the most potent natural readthrough inducers.49 The 297	  
C6’-hydroxyl group can form hydrogen bonds with the crucial 1408G residue found in 298	  
eukaryotic rRNA, whereas the C6’-NH2 group found in other aminoglycosides 299	  
cannot.22 Paromomycin also showed the lowest levels of toxicity, so selective 300	  
removal of individual saccharide rings from the original paromamine backbone 301	  
resulted in the production of a pseudo-trisaccharide compound which retained high 302	  
readthrough capacity in its simplest form. As interactions between aminoglycosides 303	  
and rRNA are largely mediated by electrostatic interactions,23 it was reasoned that 304	  
the addition of an amino group to the third ribose saccharide ring would facilitate 305	  
binding of the eukaryotic ribosome, hence further enhancing the readthrough 306	  
capacity of the novel compound. Direct comparison of compounds containing the 307	  
additional amino group with plain ribose rings bound in the same positions confirmed 308	  
this.  309	  
 310	  
Importantly, when the readthrough potential of the modified pseudo-saccharide 311	  
compound, namely NB30, was compared with gentamicin or paromomycin using an 312	  
in vitro luciferase reporter assay, it exhibited higher readthrough potential than either 313	  
natural aminoglycoside, perhaps due to a reduction in total positive charge of the 314	  
compound.49 Additionally, synthesized aminoglycoside analogues did not retain the 315	  
anti-microbial activity of parent aminoglycoside compounds, suggesting a change in 316	  
the affinity for prokaryotic ribosomal binding. Readthrough of an Usher syndrome 317	  
type 1 nonsense mutation (pR31X, CGA>UGA) in the USH1C gene, using NB30 318	  
treatment, induced lower toxicity levels than gentamicin, G418 or paromomycin. 319	  
However, the readthrough efficacy of NB30 was much lower than that of the natural 320	  
aminoglycosides.50, 51  321	  
 322	  
Amikacin shows much higher readthrough efficacy than kanamycin despite differing 323	  
by only the addition of a (S)-4-amino-2-hydroxybutanoyl (AHB) group to its N1 324	  
position (Figure 2).52 Addition of this group to the N1 position of NB30 conferred 325	  
increased readthrough potential whilst lowering its acute lethal toxicity.27 Additionally, 326	  
N1-AHB-modified aminoglycosides exhibit increased binding affinity to the ribosomal 327	  
A-site.49, 53 This resulting second-generation compound, NB54, showed greater in 328	  
vitro nonsense suppression activity than paromomycin or gentamicin in PTCs derived 329	  
from multiple disease-causing genes including: USH1C (Usher syndrome), CFTR 330	  
(CF), Dystrophin (DMD), and IDUA (Hurler Syndrome).27, 54  331	  
 332	  
Further development of NB54, to improve readthrough efficacy, led to the production 333	  
of two third-generation compounds, NB74 and NB84 which differ from NB30 and 334	  
NB54, respectively, by the addition of a (R)-6’-methyl group to the glucosamine ring 335	  
(ring I) (Figure 2).21 G418, the most potent nonsense suppressor,18, 55 is the only 336	  
aminoglycoside that has a (R)-C6’-methyl group on ring I, with a secondary alcohol at 337	  
position C6’. Additionally, gentamicin studies demonstrated that the inversion of an 338	  
absolute configuration at a single carbon atom of the C2 congener from (S)-C6’-339	  
gentamicin to (R)-C6’-gentamicin, significantly reduced toxicity of the compound, 340	  
including nephrotoxicity.37 The presence of the (R)-6’-methyl group in NB74 and 341	  
NB84 enhanced readthrough potency comparative to that of gentamicin or NB54, 342	  
while its effect on toxicity was negligible.21 Interestingly, no particular motif appeared 343	  
to be indispensable for nonsense suppression, rather each individual modification 344	  
was observed to cumulatively increase the capacity for readthrough when added to 345	  
the basic NB30 backbone. 346	  
 347	  
Of the new generation aminoglycoside-derivatives, NB84 showed the greatest 348	  
readthrough potency in an in vitro luciferase assay. Protein assays suggested that 349	  
the readthrough induced by NB84 was significantly higher than gentamicin but not 350	  
than G418.21 However, NB84 was five times less acutely toxic than G418. Novel 351	  
synthetic aminoglycoside derivatives continue to be developed with ever-increasing 352	  
readthrough efficacy; evaluation of their applicability in a clinical setting is on-going. 353	  
Recently, a novel compound NB124 has been found to mediate the highest levels of 354	  
readthrough, with significantly lower levels of ototoxicity than gentamicin, in various 355	  
CF models.56  356	  
 357	  
3.3. Non-aminoglycoside small molecule nonsense suppressors  358	  
 359	  
3.3.1. Ataluren 360	  
 361	  
High throughput screening of large libraries of small molecules has led to the 362	  
discovery of several non-aminoglycoside candidate drugs with readthrough potential, 363	  
however, controversies remain regarding their mechanism of action.57 Ataluren (also 364	  
known as Translarna™ or PTC124, Figure 3) was identified from 800,000 molecules 365	  
screened by PTC Therapeutics Inc., using a luciferase-based reporter system.58 366	  
Genes with PTCs were fused in-frame with a luciferase reporter cassette, and 367	  
luciferase activity was used as a measure of readthrough of a particular stop 368	  
mutation; higher levels of readthrough resulted in increased luciferase activity. 369	  
Despite initial concerns that the observed nonsense suppression activity actually 370	  
reflects stabilization of the steady-state activity of the luciferase enzyme, giving an 371	  
artificially high reading,59 it is now accepted that ataluren is a potent inducer of 372	  
translational readthrough of multiple PTCs across many genes, in in vitro and in vivo 373	  
models of disease.59-63 Moreover, clinical trials have demonstrated the therapeutic 374	  
benefit of ataluren’s readthrough activity: ataluren induced full-length functional 375	  
CFTR protein production in patients with CF12, 60, 64-67 and dystrophin protein 376	  
production in patients with DMD,68, 69 with a marked improvement in disease-377	  
associated phenotype. Encouragingly, ataluren  exhibited lower toxicity than 378	  
traditional aminoglycosides in several phase I/2a clinical trials.70, 71 Ataluren is 379	  
currently the first drug in its class to have received global approval for a phase III 380	  
clinical trial in the treatment of DMD in ambulatory patients aged 5 years or older.72 381	  
Only mild side-effects such as vomiting, nausea and headaches were reported, with 382	  
a number of other trials on-going.  383	  
  384	  
Ataluren is water-soluble, with good bioavailability, and can be delivered systemically 385	  
via oral administration. However, there is some question as to the suitability of this 386	  
approach for the treatment of ocular and brain disorders due to the blood-387	  
retinal/brain barrier.73 A recent report suggested that the use of a simple delivery 388	  
agent known as the START formulation (0.9% Sodium chloride, 1% Tween 80, 1% 389	  
powdered Ataluren, and 1% carboxymethylcellulose), yielded vast improvements in 390	  
the capacity for ataluren to cross the ocular surface and penetrate the eye. 391	  
Furthermore, increased suspension viscosity allowed prolonged contact of the drug 392	  
with the ocular surface, maximising absorption. Topical application of the START 393	  
formulation not only rescued the retinal and lens defects observed in the PaxSey+/- 394	  
mouse model of aniridia, but also showed a marked reduction in ocular irritation 395	  
when compared to application of a 1% aqueous ataluren suspension.73 396	  
  397	  
Recent work suggests that ataluren binds the ribosome, enhancing tRNA insertion, 398	  
with a tRNA selection bias favouring a distinct subset of tRNAs, generally leading to 399	  
the incorporation of specific amino acids at the PTC.63 These insertion biases are 400	  
thought to arise from mRNA:tRNA mispairing at codon positions one and three.  401	  
Ataluren is able to stimulate the insertion of near-cognate tRNAs that resemble those 402	  
inserted endogenously, without promoting readthrough of normal stop codons, 403	  
therefore producing proteins that are unlikely to be antigenic; an asset that appears 404	  
to be unique to ataluren.63 Chemical optimization of PTC124 by PTC Therapeutics, 405	  
led to the discovery of novel derivative PTC414, a compound suggested to increase 406	  
plasma exposure and tissue penetration whilst maintaining the favourable properties 407	  
of PTC124. Like PTC124, PTC414 demonstrated nonsense suppression ability in the 408	  
choroideremia zebrafish model chmru848, restoring sufficient protein function to 409	  
increase embryo survival and prevent retinal degeneration, whilst exhibiting improved 410	  
pharmacokinetic properties (see section 6.1).74 411	  
 412	  
3.3.2. Small molecule readthrough (SMRT) compounds 413	  
 414	  
Readthrough compounds 13 and 14 (RTC13 and RTC14, Figure 3) are SMRT 415	  
compounds identified through a high-throughput protein transcription/translation 416	  
(PTT) ELISA-based assay; a luciferase-independent system that enabled the direct 417	  
quantification of full-length protein levels resulting from successful readthrough 418	  
events.75, 76  419	  
 420	  
RTC13 and RTC14 exhibited readthrough potential, restoring dystrophin protein 421	  
expression in myoblasts isolated from the skeletal muscles of mdx mouse mutants. 422	  
Moreover, intramuscular injection of RTC13 resulted in recovery of full-length 423	  
dystrophin expression in the muscles of mdx mice, at higher levels than the observed 424	  
recovery with ataluren injection. Repeated systemic delivery of RTC13, not only 425	  
slowed the progression of myofiber degeneration characteristic of mdx mutants, but 426	  
also increased muscle strength and morphology.76, 77  427	  
 428	  
Repeat screens of additional compound libraries led to the identification of the 429	  
compounds GJ071 and GJ072 (Figure 3), which exhibited equivalent or increased 430	  
readthrough potential than RTC13 or ataluren. GJ072 and RTC13 bear structural 431	  
similarity to ataluren, sharing a common three-ring structure. However, GJ071 and 432	  
RTC14 are very structurally different. Moreover, additional compounds identified in 433	  
the primary drug screen, RTC204 and RTC219, share similar structural features to 434	  
GJ702, suggestive of the importance of this structural feature in the prediction of 435	  
readthrough efficacy and optimization of novel designer analogues.75 SMRT 436	  
compounds may eventually form the clinical basis for the treatment of disease 437	  
caused by nonsense mutations. This is reinforced by the association of these 438	  
compounds with low partition coefficient (cLogP) values, indicative of their ability to 439	  
easily permeate tissues following administration in vivo. 440	  
 441	  
4. Potential limitations of nonsense suppression therapy 442	  
 443	  
A critical factor limiting the potential application of nonsense suppression in the 444	  
treatment of ocular disease is retinal biocompatibility. NB30 showed good 445	  
biocompatibility in contrast to gentamicin, paromomycin and G418 in murine retinal 446	  
explants, causing little increase in apoptotic cell death upon administration.78 In a 447	  
similar study, PTC124 showed excellent retinal biocompatibility when compared to 448	  
gentamicin upon administration to human retinal explants.79 A key step to evaluate 449	  
preclinical retinal biocompatibility of novel nonsense suppression compounds for 450	  
human therapy requires the development of higher-order nonsense mediated animal 451	  
models for in vivo testing. This will also enable researchers to determine the passage 452	  
of drug across the blood brain barrier and determine the pharmacokinetics, including 453	  
half-life, in ocular tissue. 454	  
 455	  
A more general concern raised about nonsense suppression therapy was the 456	  
potential effect of increasing readthrough of natural stop codons within non-diseased 457	  
genes, resulting in an accumulation of misfolded, dysfunctional proteins as a 458	  
consequence of continued translation into the 3’UTR of the transcript. However, 459	  
subsequent research demonstrated increased termination of translation kinetics at 460	  
natural stop codons, when compared to PTCs.80 This was partly due to ribosome 461	  
pausing at a PTC, rendering it susceptible to the binding of nonsense suppressors 462	  
prior to termination complex-formation.80 Termination at a natural stop codon relies 463	  
on the proximity of the sequence to the 3’-poly-A tail of the mRNA transcript (Figure 464	  
4). This allows binding of the eRFs to the poly(A) binding protein (PABP), thereby 465	  
increasing the efficiency of translation termination.81 Conversely, at PTCs, the eRF 466	  
termination complex cannot interact efficiently with the 3’-PABPs due to the lack of 467	  
proximity between the PTC and the poly-A-tail of the mRNA transcript, where PABP 468	  
binds, thereby reducing the efficiency of translation termination.82 469	  
  470	  
When considering the efficacy of readthrough, it should also be highlighted that not 471	  
all full length protein restored by nonsense suppression may be functional. Several 472	  
near-cognate tRNAs, that associate with two of three nucleotides of a PTC may 473	  
induce readthrough, possibly incorporating one of several amino acids. Incorporation 474	  
of a nonfunctional amino acid at the site of a PTC may result in the production of a 475	  
full length protein with a missense mutation which attenuates protein activity or 476	  
affects protein stability.83 Genotype-phenotype correlation must be considered, for 477	  
example, there is no association in choroideremia, therefore the effect of introducing 478	  
a missense mutation in place of a nonsense variant will have no effect. However, in 479	  
aniridia, it has been suggested that missense mutations lead to a milder phenotype84 480	  
and hence this may have a slightly therapeutic effect over a loss-of-function change.  481	  
 482	  
The flanking sequence of a stop codon greatly influences the efficiency of 483	  
translational termination. Many genes have several, in-frame, natural, stop codons at 484	  
the end of the open reading-frame (ORF) to ensure that translation does not continue 485	  
into the 3’-UTR by facilitating ribosomal release.18, 19, 85-87 Interestingly, Hsp70 levels, 486	  
which are elevated in response to unfolded protein accumulation, were only slightly 487	  
increased upon administration of clinically relevant doses of gentamicin, suggesting 488	  
that PTC suppression does not cause large deleterious effects on global translation 489	  
or natural stop codon recognition.88 Additionally, overall translation rates remained 490	  
comparable between treated and non-treated mammalian cells in culture at doses of 491	  
suppression agents able to induce PTC readthrough.34, 85  492	  
 493	  
Recent research suggests that mammalian cells use nonsense suppression to 494	  
expand and/or control gene expression.89 For example, proangiogenic vascular 495	  
endothelial growth factor A (VEGFA) mRNA undergoes programmed stop codon 496	  
readthrough to generate VEGF-Ax, a unique protein isoform, which exhibits 497	  
antiangiogenic activity. A cis element in the 3’ UTR of VEGFA promotes decoding of 498	  
a UGA stop codon as a serine. Importantly, VEGF-Ax expression is depleted in 499	  
adenocarcinomas.89 Other mammalian transcripts that elicit nonsense suppression 500	  
were also identified. Furthermore, the efficiency of translation termination can be 501	  
altered in response to stress stimuli. Research suggests that in some cases 502	  
nonsense suppression may result in the production of novel immunogenic epitopes 503	  
that elicit a T-cell mediated immune response against the newly restored full length 504	  
or near-full length protein, reducing the therapeutic effectiveness.90 This highlights 505	  
the importance of monitoring immunity during nonsense suppression testing on a 506	  
case-by-case level. 507	  
 508	  
With this in mind, it is important to consider the long-term effects of global 509	  
readthrough of PTCs in a clinical context. Patients may harbour other nonsense 510	  
mutations that would be susceptible to readthrough upon treatment with nonsense 511	  
suppressors. This could potentiate off-target effects by production of previously 512	  
absent proteins that may have deleterious effects. Given this, and the significant 513	  
differences in susceptibility of mutations to readthrough by various compounds, 514	  
innovations in personalized medicine are important, for example evaluation of global 515	  
readthrough by parallel individualized genomic screening, to determine the suitability 516	  
of readthrough therapy. 517	  
 518	  
5. Nonsense-mediated decay (NMD) 519	  
 520	  
An important factor influencing the efficacy of readthrough therapies is NMD. The 521	  
NMD pathway facilitates the identification and degradation of abnormal transcripts 522	  
containing PTCs.91 The mechanism of NMD is found in all eukaryotic organisms and 523	  
is a highly conserved pathway among many species (Figure 4). In mammalian cells, 524	  
pre-mRNA splicing triggers mobilization of the exon junction complex (EJC) 525	  
approximately 20-24 nucleotides upstream of exon-exon junctions. When the 526	  
ribosome encounters a PTC that is at least 50-55 nucleotides upstream of an EJC, 527	  
the mRNA is marked for destruction by NMD machinery.  528	  
 529	  
The kinase SMG1 binds together with NMD factor UPF1 to eRF1 and eRF3, forming 530	  
the SMG-1-Upf1-eRF1-eRF3 (SURF) complex at a PTC. If an EJC is downstream of 531	  
the SURF complex, as in the case of a PTC, UPF1 is able to bind UPF2, a protein 532	  
component of the EJC, facilitating phosphorylation of UPF1 by SMG1, within the 533	  
SURF complex. This triggers release of the eRFs and recruitment of SMG5 and 534	  
SMG7. SMG5- and SMG7-mediated decay of the target mRNA occurs by 535	  
deadenylation-dependent decapping with the involvement of additional NMD-factors 536	  
such as the 5’-3’ exonuclease hXRN1.9, 91, 92 Although this model of NMD is widely 537	  
accepted, recent studies suggest the convergence of multiple factors to promote or 538	  
antagonize NMD, such as translation re-initiation.80, 93-96 539	  
  540	  
NMD naturally reduces the number of transcripts available for translational 541	  
readthrough. The level of transcripts carrying PTCs governs the efficacy of 542	  
readthrough therapy in individuals; the best responders to readthrough therapy 543	  
generally have the highest detectable levels of target transcript.97 Importantly, the 544	  
efficacy of NMD varies naturally between individuals, not only highlighting the 545	  
importance of assaying the natural level of transcript before clinical application of 546	  
nonsense suppression therapy, but also indicating that mild pharmacological 547	  
inhibition of NMD efficiency would be tolerated by a wide population.  548	  
  549	  
Strategies that inhibit NMD may viably increase the level of partially functional 550	  
truncated polypeptides or, in conjunction with nonsense suppression agents, restore 551	  
full length functional proteins, thereby alleviating disease pathology. Indeed, siRNA-552	  
mediated inhibition of UPF1,98 enhanced the efficacy of nonsense-mediated 553	  
suppression therapy.97, 99 Additionally, partial inhibition of NMD resulting in an 554	  
increased number of target transcripts, may allow for lower therapeutic doses of 555	  
readthrough compounds in the treatment of disease, with obvious benefits of 556	  
reduced cellular toxicity.  557	  
 558	  
Interestingly, NMD inhibition rescued the nonsense suppression activity for PTCs 559	  
that had previously shown no response to treatment with readthrough agents; this 560	  
has promising implications for increasing the spectrum of targets for readthrough 561	  
therapy.97 The drug amlexanox, has been described as both a putative NMD-inhibitor 562	  
and a readthrough agent that is efficient in increasing the expression of full-length 563	  
functional CFTR protein in human cells,100 presenting a combined therapeutic 564	  
opportunity for the treatment of patients with low levels of native transcript 565	  
susceptible to NMD.  566	  
 567	  
6. Nonsense suppression in ocular disease 568	  
 569	  
PTCs contribute significantly to inherited eye disease, making nonsense suppression 570	  
a viable therapeutic option. There are several examples of successful nonsense 571	  
suppression in the treatment of eye disease, including biochemical disorders such as 572	  
choroideremia, and developmental disorders, for example, aniridia.73, 101, 102 573	  
 574	  
6.1. Choroideremia 575	  
 576	  
Choroideremia is an X-linked recessive chorioretinal degeneration, with over 30% of 577	  
patients harbouring nonsense mutations in the CHM gene.103 A zebrafish model of 578	  
choroideremia has been employed to ascertain the efficacy and safety of 579	  
readthrough agents in restoring the translation of functional rab escort protein-1 (rep-580	  
1), the protein encoded by the chm gene.74, 101 The rep-1 protein is responsible for 581	  
prenylation and subsequent trafficking of rab GTPase family members to the cell 582	  
membrane. In humans, REP-1 is globally expressed throughout the body but patients 583	  
only manifest a retinal degeneration due to the REP-2 isoform compensating for the 584	  
lack of REP-1 in all tissues except for the retina. Preferential binding of certain Rab 585	  
proteins, such as Rab27a, with REP-1, prevents functional rescue.104  586	  
 587	  
In contrast to humans, zebrafish only have one rep isoform, and homozygous 588	  
nonsense mutations in the orthologous gene cause embryonic lethality at 589	  
approximately 5 days post-fertilisation (dpf).105 The chm mutant therefore provides a 590	  
robust model for testing readthrough agents, where viability of embryos beyond this 591	  
time point indicates functional rescue of rep-1 protein. Mutants dosed at 10 hours 592	  
post-fertilisation (hpf) with gentamicin or paromomycin showed a 1.7-fold increase in 593	  
survival,101 and treatment with PTC124 or PTC414 induced a 2-fold increase in 594	  
survival.74 Readthrough treatment with each compound prevented the onset of retinal 595	  
degeneration in the mutants and eye morphology appeared normal. Rescue of full-596	  
length rep-1 protein expression and restored biochemical function was confirmed 597	  
post-treatment by western blot and in vitro prenylation assay, highlighting the 598	  
translational potential of these compounds for inherited retinal disease.  599	  
 600	  
6.2. Ocular coloboma 601	  
 602	  
Ocular coloboma arises from incomplete fusion of the optic fissure during weeks 5-7 603	  
of embryogenesis, potentially affecting the iris, ciliary body, zonules, retina, choroid 604	  
and optic nerve. Ocular coloboma has been reported in up to 11.2% of blind children 605	  
worldwide, with an estimated incidence of between 0.5–7.5 per 10  000 births.106 606	  
Nonsense mutations in the PAX2 gene or CDH7 gene have been associated with 607	  
renal-coloboma syndrome and CHARGE syndrome, respectively, but there are no 608	  
known mutation-subtype preponderance. The no isthmus (noitu29a) zebrafish mutant 609	  
has a recessive nonsense mutation in pax2.1 which manifests in defective optic stalk 610	  
formation and failed optic fissure closure. Similarly, the grumpy (gupm189) mutant, 611	  
displays ocular coloboma due to a recessive nonsense mutation in lamb1. Treatment 612	  
of mutants with gentamicin and paromomycin increased readthrough efficiency of 613	  
both mutations, assayed by luciferase reporter activity. Importantly, direct exposure 614	  
to either aminoglycoside in vivo resulted in increased survival and rescued ocular 615	  
phenotypes including fusion of the optic fissure by 9 dpf.101 616	  
 617	  
6.3. Retinitis pigmentosa (RP) 618	  
 619	  
RP is a group of retinal degenerative diseases characterized primarily by the loss of 620	  
rhodopsin expression in the photoreceptors cells of the eye which ultimately leads to 621	  
a complete loss of vision. Thus, a strategy for rescuing rhodopsin expression may 622	  
restore vision.107, 108 Aminoglycoside-treatment of the S334ter rat, a model of 623	  
autosomal dominant nonsense-mediated RP caused by a nonsense mutation  in 624	  
rhodopsin (Rho), resulted in enhanced photoreceptor survival when compared to 625	  
untreated littermates.29 A 5% reduction of abnormal truncated protein expression was 626	  
sufficient to improve retinal histopathology and preserve retinal function in 627	  
gentamicin-treated rats, indicative of effective PTC readthrough. Daily injections of 628	  
gentamicin proved more effective than continuous administration via osmotic pump in 629	  
S334ter rats, and this may prove useful in the clinical application of nonsense 630	  
suppression.29  631	  
 632	  
The X-linked RP2, R120X mutation is responsible for approximately 15% of RP 633	  
cases.109, 110 This gene is ubiquitously expressed in human tissues and does not 634	  
appear to be enriched in the retina, despite patients with RP2 mutations showing 635	  
retinal dysfunction but no systemic effects. The mechanism for RP2 pathology is not 636	  
well understood, however, it may be involved in assembly and trafficking of 637	  
membrane-associated cilia proteins within the RPE and photoreceptor cells. RP2 638	  
patient fibroblasts and induced pluripotent stem cell (iPSC)-derived RPE cells were 639	  
treated with G418 (geneticin) restoring up to 20% endogenous RP2 protein.61 640	  
Previously, aminoglycosides were unable to restore full length RP2 protein 641	  
expression in RP2 patient-derived lymphoblasts.111 This may be attributable to the 642	  
surrounding nucleotide context of the PTC, or to NMD of mutant transcripts. 643	  
Interestingly, treatment of the RP2 fibroblasts with G418 resulted in an 40% increase 644	  
in R120X RP2 mRNA levels, suggesting that this drug is able to inhibit NMD, thereby 645	  
increasing the number of RP2 transcripts available for translation.11 Conversely, 646	  
ataluren treatment, which restored up to 13% endogenous RP2 protein in fibroblasts, 647	  
failed to significantly increase RP2 transcript expression, suggestive of a different 648	  
mode of action.66 649	  
 650	  
It is important to note that aminoglycoside-mediated readthrough of PTCs cannot be 651	  
predicted from genomic context of the PTC alone. Mutations in RPE65 are 652	  
associated with Leber’s Congenital Amaurosis type 2 (LCA2) and RP, characterized 653	  
by a severe early-onset retinal degeneration. For example, systemic aminoglycoside-654	  
treatment of the autosomal recessive rd12 mouse, which exhibits retinal 655	  
degeneration resulting from a PTC in Rpe65, had no effect on translational 656	  
readthrough or phenotype.29 Despite the promise of PTC-readthrough therapies, the 657	  
mechanisms of translation termination and external factors, for example epigenetic 658	  
effects, may dictate readthrough efficacy and require further elucidation. 659	  
 660	  
6.4. Usher syndrome 661	  
 662	  
Usher syndrome (USH) is the most common form of deaf-blindness worldwide with 663	  
an incidence of 3.2–6.2 per 100,000.  Type I disease (USH1) is characterized by 664	  
profound congenital sensorineural hearing loss, absent vestibular function and 665	  
retinitis pigmentosa (RP), which manifests in late childhood.  While it is possible to 666	  
compensate for the loss of hearing with hearing aids and cochlear implants, no 667	  
effective therapy is available for the ensuing RP.112-114 Several genes have been 668	  
associated with the three clinical types of Usher syndrome and nonsense mutations 669	  
account for  approximately 12 % of all USH cases.74 670	  
 671	  
Initial cell culture studies focused on the suppression of PCDH15 nonsense 672	  
mutations associated with USH type 1F to enable partial translation of functional 673	  
protein, thereby delaying the onset and/or progression of RP.50 Treatment with G418, 674	  
gentamicin, paromomycin and NB30 resulted in the production of variable full-length 675	  
protein levels as a consequence of partial readthrough of PCDH15 nonsense 676	  
mutations, although the assays employed did not confirm the functionality of full 677	  
length protein produced or evaluate the in vivo suppressive activity and toxicity.50  678	  
 679	  
More recently, translational readthrough efficacy for the treatment of USH type I 680	  
caused by the nonsense mutation p.R31X in USH1C has been investigated using a 681	  
number of nonsense suppression agents including gentamicin, ataluren, NB30 and 682	  
NB54. 51, 115 Significant rescue of full-length harmonin expression has been described 683	  
in HEK293 cells in vitro, organotypic retinal cultures ex vivo, and in harm_a1-p.31X 684	  
mice harbouring the same PTC observed in USH1F patients in vivo.  685	  
 686	  
6.5. Aniridia 687	  
  688	  
Aniridia is a congenital eye anomaly characterized by complete or partial iris 689	  
hypoplasia, frequently associated with glaucoma, cataracts, corneal anomalies and 690	  
foveal hypoplasia. It can also form part of Wilms tumour syndrome (WAGR).73, 116, 117 691	  
Isolated aniridia is predominantly caused by mutations in PAX6, 50% comprise in-692	  
frame PTCs and give rise to a more severe phenotype than rare missense 693	  
mutations.118 Therefore in cases of applying nonsense suppression therapy, spurious 694	  
missense transcripts may still be produced, conferring a milder, clinical phenotype.   695	  
 696	  
Notably, administration of gentamicin and ataluren to the Pax6sey+/- mouse model of 697	  
aniridia was not only able to inhibit the progression of the disease, but also reversed 698	  
the effects of the disorder within a specified developmental time-frame.73 Treated 699	  
animals showed improved retinal histopathology and improved responses to light 700	  
stimuli. Additionally, topical application of ataluren using the START formulation 701	  
resulted in spatial frequency levels that were comparable to responses seen in wild-702	  
type animals (see section 3.3.1). This work not only demonstrates a viable 703	  
therapeutic strategy to reverse symptoms caused by PAX6 mutations postnatally, but 704	  
also highlights the potential of readthrough agents to treat conditions caused by 705	  
dosage-sensitive genes. The first phase II clinical trial of Translarna™ for aniridia is 706	  
currently underway (NCT02647359) and the results will be eagerly awaited.  707	  
 708	  
7. Conclusion and future perspectives 709	  
 710	  
Overall, nonsense suppression therapy provides the basis for a new era of 711	  
pharmacological genetic intervention in the treatment of hereditary disorders, 712	  
reaching several million patients across the globe. In some cases, the use of 713	  
nonsense suppression therapy alone may not be sufficient to overcome the 714	  
therapeutic threshold required to restore functional protein levels and alleviate 715	  
disease phenotype. Combining NMD-inhibition compounds with nonsense 716	  
suppression drugs, or in fact the discovery of dual function drugs such as 717	  
amlexanox,119 may enhance the activity of current nonsense suppression strategies, 718	  
increasing the abundance of PTC-containing mRNA substrate. Where cell and tissue 719	  
specific changes in NMD efficiency alter disease pathology, a more personalized 720	  
approach must be employed to enhance the effectiveness of the chosen treatment, 721	  
particularly with patients who have a low baseline mRNA level, and therefore, would 722	  
benefit from NMD inhibition. Caution must be exercised as little is known about all 723	  
the mechanisms and triggers of NMD and the consequences of its attenuation. 724	  
Targeting ribosome accessory proteins, for example termination complex proteins 725	  
eRF1 and eRF3, or proteins that effect NMD efficiency, for example UPF1 may be a 726	  
feasible step in improving the efficiency of nonsense suppression agents. In addition, 727	  
it is important to consider the bioavailability of these compounds in the target tissue 728	  
and the pharmacokinetics before human application, a consideration that is 729	  
particularly relevant in treating ocular disease when compounds must cross the 730	  
blood-retina barrier at high enough concentrations to act effectively. Other modes of 731	  
delivery must be considered as intravitreal or subretinal injections may be more 732	  
suitable than exposing the whole body to potential readthrogh of PTCs elsewhere. 733	  
 734	  
Finally, although nonsense suppression has demonstrated great potential in the 735	  
treatment of eye disease in preclinical studies, implementation in a clinical setting is 736	  
required. Phase II clinical trials using Translarna™ are underway in Ophthalmology, 737	  
with translation to numerous inherited retinal diseases in the pipeline. With the 738	  
discovery of nonsense pathogenic variants associated with ocular disorders 739	  
extending to corneal dystrophies, anterior segment dysgenesis, glaucoma, multiple 740	  
retinal dystrophies and optic atrophies,120-122 the development of novel designer 741	  
compounds which exhibit improved safety profiles, more efficient PTC suppression 742	  
and optimum delivery methods will be vital in potentiating nonsense suppression as a 743	  
therapeutic strategy.  744	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Figure 1. Mechanism of protein translation and nonsense suppression.  1145	  
(A) During normal translation, free aminoacyl-tRNAs (green) diffuse into the 1146	  
ribosomal A-site where they bind complementary codons in a sequence-specific 1147	  
manner. The attached amino acid is subsequently enzymatically added to the 1148	  
growing peptide chain and the tRNA is translocated into the P-site. This process 1149	  
continues until a stop codon is encountered. (B) When the ribosome encounters a 1150	  
premature termination codon (PTC), no corresponding tRNAs exist. Therefore, 1151	  
eukaryotic release factors (eRFs), eRF1 (orange) and eRF3 (yellow) bind to the A-1152	  
site and facilitate early enzymatic release of the peptide chain. This results in the 1153	  
synthesis of a truncated protein. (C) Binding of nonsense suppressing agents (blue) 1154	  
to the ribosome affects the fidelity of translation meaning near-cognate aminoacyl-1155	  
tRNA codons (those with two conserved residues) can compete with eRFs for 1156	  
binding of the A-site. In the instances where aminoacyl-tRNAs bind to the A-site, the 1157	  
amino acid is added to the peptide chain as in normal translation and the PTC is 1158	  
bypassed. This readthrough allows the synthesis of a full-length protein by 1159	  
incorporating an amino acid in place of the PTC (red oval). 1160	  
 1161	  
Figure 2. Structures of aminoglycosides used to synthesize novel designer 1162	  
aminoglycosides.  1163	  
Structural features of natural aminoglycosides paromomycin, amikacin and G418 1164	  
were combined to produce designer aminoglycosides NB30, NB54, NB74 and NB84. 1165	  
Designer aminoglycosides incorporated the three ring pseudo-trisaccharide 1166	  
backbone of paromomycin (red), ring II holds C1’-AHB of amikacin (magenta), and 1167	  
ring I includes C6’-methyl group of G418 (blue) to produce a number of novel 1168	  
compounds.  NB84 has all of these structural features and has shown the most 1169	  
potential for nonsense suppression. 1170	  
 1171	  
Figure 3. Structures of non-aminoglycoside small molecule readthrough compounds. 1172	  
Ataluren (PTC124) has demonstrated potent capacity for readthrough and was 1173	  
discovered from a high-throughput luciferase assay screen of a large compound 1174	  
library. RTC13, RTC14, GJ071 and GJ072 were similarly identified from a high-1175	  
throughput protein transcription-translation ELISA-based screen and have also 1176	  
demonstrated nonsense suppression. These compounds have been used to make a 1177	  
number of other promising analogues that may retain the capacity for readthrough. 1178	  
 1179	  
Figure 4. Translation termination and nonsense-mediated decay (NMD). 1180	  
(A) During normal translation the ribosome will move along the mRNA and displace 1181	  
the exon-junction complexes (EJC) (magenta) as it progresses. It will only stop when 1182	  
it reaches the terminal stop codon where formation of the termination complex 1183	  
including recruitment of release factors eRF1 (orange) and eRF3 (yellow) facilitate 1184	  
translational termination and release of the peptide/ribosome. This release is very 1185	  
rapid as eRFs bind the adjacent poly-A binding proteins (PABP) (blue) localised to 1186	  
the 3’-end of the mRNA, which increases the kinetics of termination at a natural stop 1187	  
codon. (B) When the ribosome encounters a premature termination codon (PTC) the 1188	  
ribosome pauses and the eRFs bind to facilitate translational termination. However, 1189	  
the kinetics of termination are much slower at a PTC because the distal position of 1190	  
the PTC does not facilitate PABP binding. eRFs recruit UPF1 (green) which in turn 1191	  
binds kinase SMG1 (blue) to form the SURF complex. When this complex is at least 1192	  
50-55 nucleotides upstream of an EJC, UPF1 can bind UPF2 (green), a component 1193	  
of the EJC, to facilitate phosphorylation of UPF1 by SMG1 to (C) release eRFs and 1194	  
recruit two further proteins, SMG5/7 (blue). This triggers NMD via the recruitment of 1195	  
various factors including hXRN1 exonuclease (red), resulting in decreased mRNA 1196	  
levels. 1197	  
 1198	  
Table 1. Amino acids that can replace PTCs through binding of near-cognate tRNAs 1199	  
during readthrough. 1200	  
